Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products
WITHDRAWN  

Product information

Lintuzumab

EU orphan designation number: EU/3/09/626
Active ingredient: Lintuzumab
Indication: Treatment of myelodysplastic syndromes
Sponsor: Seattle Genetics UK Limited
c/o Jordans Limited, 20-22 Bedford Row, London WC1R 4JS , United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/05/2009 Centralised Orphan - Designation EMEA/OD/117/08 (2009)3455 of 29/04/2009
17/08/2011 Centralised Orphan - Removal of orphan designation from Community Register